Published on 27 Jan 2024 on Simply Wall St. via Yahoo Finance
Analysts Are More Bearish On Coherus BioSciences, Inc. (NASDAQ:CHRS) Than They Used To Be
The latest analyst coverage could presage a bad day for Coherus BioSciences, Inc. (NASDAQ:CHRS), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analysts seeing grey clouds on the horizon.
After the downgrade, the eight analysts covering Coherus BioSciences are now predicting revenues of US$374m in 2024. If met, this would reflect a substantial 77% improvement in sales compared to the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 65% to US$0.69. However, before this estimates update, the consensus had been expecting revenues of US$434m and US$0.50 per share in losses. Ergo, there's been a clear change in sentiment, with the analysts administering a notable cut to next year's revenue estimates, while at the same time increasing their loss per share forecasts.
View our latest analysis for Coherus BioSciences